Evidence map›Paper›PMID 27442440›Full record

ArticlePloS one2016

Adherence to Concurrent Tuberculosis Treatment and Antiretroviral Treatment among Co-Infected Persons in South Africa, 2008-2010.

Ernesha Webb Mazinyo, Lindsay Kim, Sikhethiwe Masuku, Joey L Lancaster, Ronel Odendaal, Margot Uys, Laura Jean Podewils, Martie L Van der Walt

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 3 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Ernesha Webb MazinyoTuberculosis HIV/AIDS Treatment Support and Integrated Therapy (THAT'SIT), Johannesburg, South Africa and Foundation for Professional Development, Pretoria, South Africa.
Lindsay KimEpidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Sikhethiwe MasukuTuberculosis Epidemiology and Intervention Research Unit, South African Medical Research Council, Pretoria, South Africa.
Joey L LancasterTuberculosis Epidemiology and Intervention Research Unit, South African Medical Research Council, Pretoria, South Africa.
Ronel OdendaalTuberculosis Epidemiology and Intervention Research Unit, South African Medical Research Council, Pretoria, South Africa.
Margot UysTuberculosis HIV/AIDS Treatment Support and Integrated Therapy (THAT'SIT), Johannesburg, South Africa and Foundation for Professional Development, Pretoria, South Africa.
Laura Jean PodewilsDivision of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Martie L Van der WaltTuberculosis Epidemiology and Intervention Research Unit, South African Medical Research Council, Pretoria, South Africa.
South African Medical Research Council · ZACenters for Disease Control and Prevention · USFoundation for Professional Development · ZA

Funding

NCHHSTP CDC HHS U51 PS000729
6 · The paper itself

Abstract

backgroundAdherence to tuberculosis (TB) treatment and antiretroviral therapy (ART) reduces morbidity and mortality among persons co-infected with TB/HIV. We measured adherence and determined factors associated with non-adherence to concurrent TB treatment and ART among co-infected persons in two provinces in South Africa.

methodsA convenience sample of 35 clinics providing integrated TB/HIV care was included due to financial and logistic considerations. Retrospective chart reviews were conducted among persons who received concurrent TB treatment and ART and who had a TB treatment outcome recorded during 1 January 2008-31 December 2010. Adherence to concurrent TB and HIV treatment was defined as: (1) taking ≥80% of TB prescribed doses by directly observed therapy (DOT) as noted in the patient card; and (2) taking >90% ART doses as documented in the ART medical record during the concurrent treatment period (period of time when the patient was prescribed both TB treatment and ART). Risk ratios (RRs) and 95% confidence intervals (CIs) were used to identify factors associated with non-adherence.

resultsOf the 1,252 persons receiving concurrent treatment, 138 (11.0%) were not adherent. Non-adherent persons were more likely to have extrapulmonary TB (RR: 1.71, 95% CI: 1.12 to 2.60) and had not disclosed their HIV status (RR: 1.96, 95% CI: 1.96 to 3.76).

conclusionsThe majority of persons with TB/HIV were adherent to concurrent treatment. Close monitoring and support of persons with extrapulmonary TB and for persons who have not disclosed their HIV status may further improve adherence to concurrent TB and antiretroviral treatment.

Indexed as

Medication AdherenceAdultAnti-Retroviral AgentsAntitubercular AgentsCoinfectionDemographyFemaleHIV InfectionsHumansMaleMiddle AgedMultivariate AnalysisSouth AfricaTuberculosisAnti-Retroviral AgentsAntitubercular Agents

Identifiers

PMID27442440
PMCPMC4956242
OpenAlexW2486280420

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.